APOA1 Polyclonal antibody

APOA1 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 31265-1-AP

Synonyms

---

Validation Data Gallery

• 

  WB analysis using 31265-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 31265-1-AP (APOA1 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 31265-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 31265-1-AP (APOA1 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: mouse liver tissue, HepG2 cells, mouse lung tissue, mouse spleen tissue

Recommended dilution

• Western Blot (WB): WB : 1:1000-1:4000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

31265-1-AP targets APOA1 in WB, ELISA applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: Recombinant protein
• Full Name: apolipoprotein A-I
• Calculated Molecular Weight: 31 kDa
• Observed Molecular Weight: 26 kDa
• GenBank Accession Number: BC005380
• Gene Symbol: APOA1
• Gene ID (NCBI): 335
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity Purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

ApoA1 is a major protein component of high density lipoproteins (HDL) which is associated with reversed cholesterol transport, lipid/cholesterol binding, lecithin/cholesterol acyltransferase (LCAT) activation and specific receptors binding. It is synthesized in the liver and small intestine. Defects of ApoA1 cause low HDL level and systemic non-neuropathic amyloidosis. Serum concentration of ApoA1 is inversely related to the risk of developing atherosclerosis. This antibody was generated against the C-terminal region of human ApoA1.